Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the ...

EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration partner Bayer has submitted an application to the Center of Drug ...

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer ...

Discover the study supports the potential of neoadjuvant androgen deprivation therapy as an adjunctive therapy in HRLPC.

Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

A physician survey finds a gap between guidelines and real-world clinical practice in treatment intensification for ...

Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

Discover Baduanjin, a traditional Chinese exercise, and a potential complementary therapy for patients with prostate cancer ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

More research is needed to address barriers to therapeutic monitoring of prostate cancer patients on androgen deprivation therapy, according to researchers.